North American Scientific Introduces Serial Tomotherapy Advanced Treatment Solution
Posted on: Monday, 10 October 2005, 06:00 CDT
The Company's NOMOS(R) Radiation Oncology Division to Showcase nomosSTAT(TM) at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO)
North American Scientific, Inc. (Nasdaq:NASI) announced today that its NOMOS Radiation Oncology division will introduce nomosSTAT(TM), its new serial tomotherapy advanced treatment solution, at the upcoming 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) scheduled to be held in Denver, October 16-19, 2005, Booth No. 737.
nomosSTAT integrates the Company's core serial tomotherapy delivery products, MIMiC(R) and AutoCrane(TM), with a single user interface inside and outside the treatment room. This new interface, with network connection to the CORVUS IMRT inverse planning system, streamlines the delivery process, improving efficiency and increasing patient throughput. As the only after-market, add-on serial tomotherapy delivery package offered as an upgrade to an existing linear accelerator (linac), it provides an affordable, turnkey solution for facilities wanting to implement IMRT as part of their cancer treatment arsenal without the need to purchase a costly, IMRT-enabled linac. nomosSTAT is expected to be available for shipment early in 2006, following FDA 510(k) approval.
"nomosSTAT embodies our advanced IMRT technology within an architecture that increases treatment efficiencies and that we believe will support future advances in image guidance and adaptive therapy," said L. Michael Cutrer, President and Chief Executive Officer of North American Scientific. "By utilizing our technology, premier installation and commissioning services, facilities will be able to quickly upgrade their existing equipment and immediately implement state-of-the-art, IMRT-based treatment options for patient care. The nomosSTAT introduction is another example of our continued commitment to providing our customers with affordable solutions to satisfy their emerging needs."
About North American Scientific
North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with a set of tools for the treatment of various types of cancers. They include radioisotope-based brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera; Intensity Modulated Radiation Therapy (IMRT); and Image Guided Radiation Therapy (IGRT). IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. The Company's principal IMRT products are marketed under the trade names PEACOCK(R) and CORVUS. The Company's IGRT product, BAT, provides fast and accurate targeting and localization of a treatment volume on a daily basis. Over 500 hospitals and research sites worldwide are equipped with the Company's clinically proven PEACOCK, CORVUS (our proprietary treatment planning software), BAT and ancillary treatment solutions. Please visit www.nasmedical.com for more information.
Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, uncertainties relating to drug discovery and clinical development processes, the impact of competitive products and technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its brachytherapy products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, the impact of competitive products and pricing, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue, and the risk factors included in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.
Source: Business Wire
Related Articles
- EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy
- Devon Energy Provides Forward-Looking Estimates of Production, Reserve Additions and Capital Expenditures
- Littleton Radiation Oncology One of Several New Cancer Treatment Centers Now Offering BSD Medical's Hyperthermia Therapy
- Metabasis Therapeutics Presents Results of a Clinical Study for Its Novel Liver-Targeted Product Candidate for the Treatment of HCC at American Association for Cancer Research
- Candela Introduces New Products at American Academy of Dermatology 2007 Conference
- Bernanke Says Fed Policy Must Be Forward-looking
- Hollis-Eden Pharmaceuticals Responds to Sources Sought Notice From Department of Defense for Acute Radiation Syndrome Therapy for U.S. Forces
- Westinghouse Lauds Progress Energy for Proactive, Forward-Looking Approach to Nuclear Fleet Expansion
- IsoRay Medical's Cesium-131 Brachytherapy Treatment Combined With External Beam Radiation Therapy for the First Time at the Arnold Palmer Prostate Center at Eisenhower Medical Center
- Hollis-Eden Pharmaceuticals Releases Response to Department of Health and Human Services Draft Request for Proposal For Acute Radiation Syndrome Therapy
 |
 |
User Comments (0)
RSS Feeds